Latest Insider Transactions at Reneo Pharmaceuticals, Inc. (RPHM)
This section provides a real-time view of insider transactions for Reneo Pharmaceuticals, Inc. (RPHM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Reneo Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Reneo Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Direct |
102,076
+50.0%
|
-
|
|
Oct 07
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Indirect |
345,739
+50.0%
|
-
|
|
Oct 04
2024
|
Nicholas A Saccomano President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,556
+50.0%
|
-
|
|
Oct 04
2024
|
Jason A. Leverone Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,331
+50.0%
|
-
|
|
Oct 04
2024
|
R Michael Carruthers |
BUY
Grant, award, or other acquisition
|
Direct |
4,939
+47.57%
|
-
|
|
Sep 25
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
68,746
+1.95%
|
$68,746
$1.5 P/Share
|
|
Sep 24
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
29,600
+0.87%
|
$29,600
$1.41 P/Share
|
|
Sep 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
806
+0.02%
|
$806
$1.4 P/Share
|
|
Sep 17
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
55,300
+1.62%
|
$55,300
$1.36 P/Share
|
|
Sep 16
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
172,747
+4.97%
|
$172,747
$1.37 P/Share
|
|
Sep 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
150,000
+4.57%
|
$150,000
$1.31 P/Share
|
|
Sep 12
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
36,176
+1.2%
|
$36,176
$1.4 P/Share
|
|
Aug 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
100,487
+3.3%
|
$100,487
$1.41 P/Share
|
|
Aug 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
171,339
+5.68%
|
$171,339
$1.39 P/Share
|
|
May 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
414,281
+7.21%
|
$414,281
$1.55 P/Share
|
|
Aug 28
2023
|
Ashley Hall Chief Development Officer |
SELL
Open market or private sale
|
Direct |
15,625
-28.29%
|
$93,750
$6.28 P/Share
|
|
Aug 28
2023
|
Ashley Hall Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+22.05%
|
$15,625
$1.8 P/Share
|
|
Jul 26
2023
|
Michael G Grey |
SELL
Bona fide gift
|
Direct |
50,000
-100.0%
|
-
|
|
Jun 23
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-2.92%
|
$700,000
$7.1 P/Share
|
|
May 08
2023
|
Niall O'Donnell Director |
BUY
Open market or private purchase
|
Indirect |
125,000
+5.4%
|
$1,000,000
$8.0 P/Share
|
|
Sep 01
2022
|
Michael Cruse Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
7,500
+35.38%
|
$22,500
$3.39 P/Share
|
|
Aug 31
2022
|
Michael G Grey |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$50,000
$1.97 P/Share
|
|
Aug 31
2022
|
Michael Cruse Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
3,212
+34.14%
|
$9,636
$3.21 P/Share
|
|
Aug 30
2022
|
Michael Cruse Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
1,845
+38.2%
|
$5,535
$3.19 P/Share
|
|
Aug 30
2022
|
Michael Cruse Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
975
+2.98%
|
$2,925
$3.16 P/Share
|
|
Aug 29
2022
|
Michael Cruse Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
1,140
+50.0%
|
$3,420
$3.24 P/Share
|
|
Aug 29
2022
|
Michael Cruse Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
83
+0.27%
|
$249
$3.24 P/Share
|
|
Aug 12
2022
|
Alejandro Dorenbaum Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
22,348
-42.69%
|
-
|
|
Dec 10
2021
|
Michael Cruse Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+46.21%
|
-
|
|
Dec 10
2021
|
Alejandro Dorenbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+36.43%
|
-
|
|
Dec 10
2021
|
Gregory J. Flesher President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+47.71%
|
-
|
|
Dec 10
2021
|
Vineet R. Jindal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+45.05%
|
-
|
|
Nov 12
2021
|
Ashley Hall Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Aug 25
2021
|
Michael Cruse Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$17,500
$7.45 P/Share
|
|
Aug 25
2021
|
Gregory J. Flesher President and CEO |
BUY
Open market or private purchase
|
Direct |
8,000
+50.0%
|
$64,000
$8.0 P/Share
|
|
Aug 25
2021
|
Vineet R. Jindal Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$35,000
$7.44 P/Share
|
|
Jul 14
2021
|
Wendy S. Johnson Chief Development Officer |
SELL
Open market or private sale
|
Direct |
111,736
-100.0%
|
$893,888
$8.5 P/Share
|
|
Jul 14
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
111,736
+5.11%
|
$893,888
$8.5 P/Share
|
|
Jul 08
2021
|
Wendy S. Johnson Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
111,736
+50.0%
|
$111,736
$1.97 P/Share
|
|
Jun 23
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
20,710
+1.04%
|
$186,390
$9.28 P/Share
|
|
Jun 22
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
14,615
+0.75%
|
$116,920
$8.72 P/Share
|
|
Jun 21
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
32,659
+1.67%
|
$293,931
$9.03 P/Share
|
|
Jun 08
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
16,605
+0.87%
|
$149,445
$9.5 P/Share
|
|
Jun 04
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
257
+0.01%
|
$2,313
$9.42 P/Share
|
|
Jun 03
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
12,100
+0.64%
|
$108,900
$9.25 P/Share
|
|
May 28
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
14
+0.0%
|
$126
$9.5 P/Share
|
|
May 27
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
1,120
+0.06%
|
$10,080
$9.26 P/Share
|
|
May 26
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
5,915
+0.32%
|
$53,235
$9.38 P/Share
|
|
Apr 13
2021
|
Michael G Grey |
BUY
Conversion of derivative security
|
Indirect |
20,162
+4.34%
|
-
|
|
Apr 13
2021
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+9.72%
|
$3,000,000
$15.0 P/Share
|